Research advances in the efficacy and safety of ofatumumab in patients with relapsing multiple sclerosis
10.19845/j.cnki.zfysjjbzz.2025.0007
- VernacularTitle:奥法妥木单抗在复发型多发性硬化患者中有效性和安全性的研究进展
- Author:
Yue ZHAO
1
;
Lei LI
1
Author Information
1. Stroke Centre， The Second Affiliated Hospital of Harbin Medical University， Harbin 150086， China
- Publication Type:Journal Article
- Keywords:
Multiple sclerosis;
Anti-CD20 monoclonal antibody;
Ofatumumab;
Clinical efficacy and safety
- From:
Journal of Apoplexy and Nervous Diseases
2025;42(1):34-37
- CountryChina
- Language:Chinese
-
Abstract:
Ofatumumab is a fully humanized anti-CD20 monoclonal antibody approved for the disease-modifying treatment of multiple sclerosis in the remission stage. Its Fab segment selectively binds to and inhibits CD20 and induces B-cell lysis， thereby controlling disease progression. This article reviews the research advances in the efficacy and safety of ofatumumab in patients with relapsing multiple sclerosis.
- Full text:2025071509500846350奥法妥木单抗在复发型多发性硬化患者中有效性和安全性的研究进展.pdf
